This paper is only available as a PDF. To read, Please Download here.
Objectives
To compare patient satisfaction with anesthesia after first-trimester surgical abortions
among patients receiving intravenous ketamine vs. IV fentanyl for procedural sedation.
Methods
This was a randomized noninferiority trial comparing IV ketamine to IV fentanyl for
surgical abortions up to 13 6/7 weeks’ gestation. Patients were randomized to receive
midazolam 2 mg IV and either ketamine 200–500 mcg/kg IV over two minutes, repeated
every five minutes until appropriate analgesia was achieved, or fentanyl 0.5–1 mcg/kg
IV over two minutes, repeated every five minutes until appropriate analgesia was achieved.
The primary outcome, patient satisfaction, was measured using the Iowa Satisfaction
with Anesthesia Scale (ISAS) immediately post-procedure. Secondary outcomes included
postoperative pain and additional pain medication given. We calculated a sample size
of 84 with a noninferiority margin of 0.6 on the ISAS scale with 80% power, one-sided
type 1 error of 0.025, and further increased this number to 110 to account for potential
dropout.
Results
From April to October 2021, 184 patients were screened and 110 were randomized (57
to ketamine and 53 to fentanyl). Demographics were similar between groups. The primary
outcome, patient satisfaction with anesthesia, was noninferior in the ketamine group
(mean score, 2.4; SD, 0.8) compared with the fentanyl group (mean score, 2.2; SD,
0.9) with a risk difference of 0.20 (95% CI, 0.11–0.52). Secondary outcomes were similar
between the groups.
Conclusions
Compared with IV fentanyl, IV ketamine is noninferior for patient satisfaction with
anesthesia when used for procedural sedation for first-trimester surgical abortions.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
